Horn et al. assessed the administration of ensartinib in a phase I/II trial, which enrolled 37 patients with solid tumors in the dose-escalation part and 60 ALK-positive NSCLC patients in the dose-expansion part. Here, ALK is linked to non-small cell lung carcinoma.